Summary
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive group of mature T-cell malignancies, representing approximately 10–15% of non-Hodgkin lymphomas in the US.
CHOP remains the standard first-line treatment, but its intensive cytotoxic profile limits use in some patients.
ADCETRIS (brentuximab vedotin) is the only approved agent in the first-line setting, while therapies such as BELEODAQ, POTELIGEO, XALKORI, and EZHARMIA are primarily applicable to selected subtypes or treatment settings.
The key late-stage candidates poised to drive significant changes during the upcoming forecast period include Duvelisib (COPIKTRA; Secura Bio), golidociti...
